DTRA announces contract with Stabilitech

Stabilitech has announced a $4 million contract with the United States Defense Threat Reduction Agency to provide vaccine stabilization procedures.
According to ScienceBusiness.net, Stabilitech will provide vaccine stockpiling technologies for the Department of Defense agency. Two products - an ajuvenated and an adeno-virus vaccine - will be combined to combat a key bacterial pathogen target.

“We are very pleased to have been selected by DTRA to work on these key projects for the US Department of Defense," Barbara Domayne-Hayman, Stabilitech’s CEO, said. "We believe the work will demonstrate the broad applicability of our stabilisation technology and enable the DTRA to achieve its goals for these important biodefense vaccines. In addition, this non-dilutive funding is important as Stabilitech continues to grow.”
Stabillitech is a London-based company focused on vaccine stabilization. Founded in 2002, the company’s proprietary technology is intended to safeguard multi-faceted biopharmaceutical challenges. Stablitech also recently received a Technology Strategy Board grant from the British government.
President Obama’s budget for 2011 included more than $500 million towards upgrading the nation’s response capabilities to bioterror threats. A congressional, bi-partisan commission report announced in October 2009 that the country was not doing enough to keep pace with the growing threat of biological weapons.